Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Follows, G.
301  Ergebnisse:
Personensuche X
?
1

Final safety and efficacy results of copanlisib monotherapy..:

Dreyling, M. ; Santoro, A. ; Mollica, L....
Hematological Oncology.  41 (2023)  S2 - p. 560-562 , 2023
Link: https://doi.org/10.1002/..
 
?
2

P666: ACALABRUTINIB ± OBINUTUZUMAB VS OBINUTUZUMAB + CHLORA..:

Sharman, J. P. ; Egyed, M. ; Jurczak, W....
HemaSphere.  6 (2022)  - p. 564-565 , 2022
Link: https://doi.org/10.1097/..
 
?
3

MODIFICATION OF ESCALATED BEACOPP WITH DACARBAZINE SUBSTITU..:

Santarsieri, A. ; Sturgess, K. ; Brice, P....
Hematological Oncology.  39 (2021)  S2 - p. , 2021
Link: https://doi.org/10.1002/..
 
?
4

PCN325 Health Utility in Relapsed/Refractory Diffuse Large ..:

Casasnovas, R.O. ; Daniele, P. ; Tremblay, G....
Value in Health.  23 (2020)  - p. S479-S480 , 2020
Link: https://doi.org/10.1016/..
 
?
5

A PHASE 2B STUDY OF SELINEXOR IN PATIENTS WITH RELAPSED/REF..:

Kalakonda, N. ; Cavallo, F. ; Follows, G....
Hematological Oncology.  37 (2019)  S2 - p. 62-64 , 2019
Link: https://doi.org/10.1002/..
 
?
6

SAFETY ANALYSIS OF PATIENTS WITH A MEDICAL HISTORY OF RESPI..:

Zinzani, P.L. ; Santoro, A. ; Leppä, S....
Hematological Oncology.  37 (2019)  S2 - p. 389-390 , 2019
Link: https://doi.org/10.1002/..
 
?
7

EFFICACY AND SAFETY IN HIGH‐RISK RELAPSED OR REFRACTORY IND..:

Dreyling, M. ; Santoro, A. ; Leppä, S....
Hematological Oncology.  37 (2019)  S2 - p. 387-389 , 2019
Link: https://doi.org/10.1002/..
 
?
8

MODIFICATION OF ESCALATED BEACOPP WITH DACARBAZINE / PROCAR..:

Follows, G. ; Santarsieri, A. ; Sturgess, K....
Hematological Oncology.  37 (2019)  S2 - p. 490-491 , 2019
Link: https://doi.org/10.1002/..
 
?
9

COPANLISIB TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTOR..:

Panayiotidis, P. ; Kellner, A. ; Follows, G.A....
Hematological Oncology.  37 (2019)  S2 - p. 399-400 , 2019
Link: https://doi.org/10.1002/..
 
?
10

PO-0737: Is there a role for hippocampal sparing consolidat..:

Buckley, H. ; Follows, G. ; Ajithkumar, T.
Radiotherapy and Oncology.  127 (2018)  - p. S377-S378 , 2018
Link: https://doi.org/10.1016/..
 
?
11

COPANLISIB IN PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT..:

Dreyling, M. ; Santoro, A. ; Mollica, L....
Hematological Oncology.  35 (2017)  S2 - p. 119-120 , 2017
Link: https://doi.org/10.1002/..
 
?
12

Advanced Hodgkin lymphoma in the east of England cancer net..:

Russell, J. ; Collins, A. ; Fowler, A....
Hematological Oncology.  35 (2017)  S2 - p. 318-319 , 2017
Link: https://doi.org/10.1002/..
 
?
13

OUTCOMES OF PATIENTS POST IBRUTINIB TREATMENT FOR RELAPSED/..:

Follows, G.A. ; CLL Forum, U.K.
Hematological Oncology.  35 (2017)  S2 - p. 237-238 , 2017
Link: https://doi.org/10.1002/..
 
?
14

A PHASE 2B RANDOMIZED STUDY OF SINGLE AGENT SELINEXOR IN PA..:

Casasnovas, R. ; Westin, J. ; Thieblemont, C....
Hematological Oncology.  35 (2017)  S2 - p. 191-192 , 2017
Link: https://doi.org/10.1002/..
 
?
15

IBRUTINIB FOR RELAPSED / REFRACTORY CLL: AN UPDATE OF THE U..:

Follows, G.A. ; CLL Forum, U.K.
Hematological Oncology.  35 (2017)  S2 - p. 238-239 , 2017
Link: https://doi.org/10.1002/..
 
1-15